IDEAYA Biosciences (IDYA) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 225.3% versus a gain of 34.8%. Over five years, TNGX leads with a +69.7% price change compared with +56.1% for IDYA. Tango Therapeutics is the larger company by market cap ($4.01 billion vs $3.48 billion), about 1.2 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs +48.3%).
IDEAYA Biosciences converts more of its revenue into profit, with a net margin of -52.0% versus -162.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | TNGX |
|---|---|---|
| Share price | $36.11 | $23.81 |
| Market cap | $3.48B | $4.01B |
| 1-day change | +0.14% | +5.49% |
| YTD return | +4.45% | +168.74% |
| 1-year return | +34.79% | +225.27% |
| 5-year return | +56.12% | +69.71% |
| EPS (TTM) | $-1.94 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $62.38M |
| Revenue growth (YoY) | +3024.43% | +48.29% |
| Net income (latest FY) | $-113.70M | $-101.59M |
| Operating margin | -72.84% | -178.39% |
| Net margin | -51.99% | -162.85% |
| 52-week high | $42.68 | $34.39 |
| 52-week low | $26.20 | $6.69 |
| Distance from 52-week high | -15.39% | -30.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +46.08% | +89.75% |
| Average volume | 779.48K | 2.65M |
| Shares outstanding | 96.49M | 168.61M |
| Employees | 145 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed IDYA by 190.5 percentage points over the past year.
- IDEAYA Biosciences is more profitable, keeping -52.0 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +48.29%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
IDYA vs TNGX FAQ
Which is bigger, IDEAYA Biosciences or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $4.01B compared with $3.48B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, IDYA or TNGX?
TNGX returned +225.27% over the past 12 months, compared with +34.79% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.